Skip to content

Trial Summary

A first-in-human study of VG161 in participants with advanced malignant tumours that have not responded to conventional therapies.

Acronym:

VG161-A101

ACTRN/NCT /ethics:

ACTRN12620000244909

Scientific title:

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG161 in Subjects with Advanced Malignant Solid Tumors that are Refractory to Conventional Therapies

Sponsor / Cooperative group:

Virogin Biotech Australia

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexAll
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2020-03-16
Anticipated End Date2022-03-31

Participating Hospitals

HospitalSouthern Oncology Clinical Research Unit
Clinical Trial CoordinatorMeggan O'Riley
EmailMeggan.ORiley@socru.org.au
Phone0491 679 039
Principal Investigator-
Recruitment Status-